Palo Alto Investors Has Upped Its Sage Therapeutics (SAGE) Stake; Blackrock Muniyield Quality Fund II Has 2.38 Sentiment

April 19, 2018 - By Clifton Ray

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Palo Alto Investors Llc increased Sage Therapeutics Inc (SAGE) stake by 2.99% reported in 2017Q4 SEC filing. Palo Alto Investors Llc acquired 23,555 shares as Sage Therapeutics Inc (SAGE)’s stock declined 6.84%. The Palo Alto Investors Llc holds 810,806 shares with $133.55M value, up from 787,251 last quarter. Sage Therapeutics Inc now has $7.86B valuation. The stock decreased 0.38% or $0.66 during the last trading session, reaching $171.78. About 146,651 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 19, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Blackrock Muniyield Quality Fund II Inc (MQT) investors sentiment increased to 2.38 in 2017 Q4. It’s up 1.67, from 0.71 in 2017Q3. The ratio has improved, as 19 investment professionals increased and opened new equity positions, while 8 decreased and sold stakes in Blackrock Muniyield Quality Fund II Inc. The investment professionals in our database now have: 2.55 million shares, up from 2.38 million shares in 2017Q3. Also, the number of investment professionals holding Blackrock Muniyield Quality Fund II Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 6 Increased: 11 New Position: 8.

The stock decreased 0.17% or $0.02 during the last trading session, reaching $12. About 13,370 shares traded. BlackRock MuniYield Quality Fund II, Inc. (MQT) has declined 5.57% since April 19, 2017 and is downtrending. It has underperformed by 17.12% the S&P500.

Robinson Capital Management Llc holds 1.72% of its portfolio in BlackRock MuniYield Quality Fund II, Inc. for 272,237 shares. Tradewinds Capital Management Llc owns 60,761 shares or 0.39% of their US portfolio. Moreover, Garrison Bradford & Associates Inc has 0.22% invested in the company for 20,000 shares. The Minnesota-based Sit Investment Associates Inc has invested 0.1% in the stock. Advisors Asset Management Inc., a Colorado-based fund reported 217,486 shares.

Investors sentiment increased to 1.49 in 2017 Q4. Its up 0.28, from 1.21 in 2017Q3. It improved, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Brown Advisory stated it has 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Artal Gp invested 0.19% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Eam Invsts Limited Liability Co holds 0.43% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 19,896 shares. Susquehanna Gru Ltd Liability Partnership has invested 0.02% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Eagle Asset Mgmt reported 0.56% stake. 26,347 are held by Rmb Cap Lc. Cibc Ww Mkts Inc owns 4,430 shares. Pacad stated it has 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Raymond James Svcs Advsrs Inc has 1,441 shares for 0% of their portfolio. World Asset Management Inc owns 1,437 shares for 0.01% of their portfolio. Great West Life Assurance Com Can reported 4,162 shares or 0% of all its holdings. Mutual Of America Capital Mngmt Ltd Liability Corporation holds 0.09% or 35,365 shares. Highbridge Management Lc holds 0% or 1,390 shares. Illinois-based Citadel has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Moreover, Amundi Pioneer Asset Mgmt Incorporated has 0.03% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE).

Since December 14, 2017, it had 0 insider buys, and 3 selling transactions for $27.36 million activity. The insider Robichaud Albert sold $9.57 million. 44,000 Sage Therapeutics, Inc. (NASDAQ:SAGE) shares with value of $7.80M were sold by Kanes Stephen. 58,139 shares were sold by PAUL STEVEN M, worth $10.00 million on Tuesday, March 6.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 56 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, February 22 by RBC Capital Markets. Cowen & Co maintained it with “Buy” rating and $90.0 target in Tuesday, September 12 report. Leerink Swann maintained the stock with “Buy” rating in Thursday, December 7 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Outperform” rating by BMO Capital Markets on Thursday, September 14. Stifel Nicolaus initiated it with “Buy” rating and $90 target in Monday, November 14 report. The stock has “Buy” rating by Needham on Tuesday, September 12. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by RBC Capital Markets on Monday, October 16. As per Tuesday, September 13, the company rating was initiated by Raymond James. Needham maintained the stock with “Buy” rating in Tuesday, June 13 report. The rating was maintained by Stifel Nicolaus on Thursday, November 2 with “Buy”.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>